Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does anyone have recent (2023) experience in fighting with insurance companies?
My 2 ongoing endeavors:
A - mine) https://stocktwits.com/rafunrafun/message/508308579
B1 - parents) https://stocktwits.com/rafunrafun/message/507683335
B2 - parents) https://stocktwits.com/rafunrafun/message/508306688
This guy makes a great point.
https://stocktwits.com/rafunrafun/message/507657914
https://stocktwits.com/rafunrafun/message/507653860
I just sent the following email to IR & KM. A likelihood of a reply is less than 1%.
Scripts for week ending January 13, 2023
Drug Industry TRx: -0.6% w/w; +9.5% y/y
Vascepa
TRx 60,503; +5.9% (+3,376) w/w; -19.4% y/y
NRx 28,748; +13.6% (+3,450) w/w; -17.9% y/y
Ref 31,754; -0.2% (-75) w/w; -20.8% y/y
Fake Vascepa
TRx 46,304; +7.0% (+3,027) w/w; As % of total V: 43.4%
NRx 23,116; +14.9% (+3,001) w/w; As % of total V: 44.6%
Ref 23,187; +0.1% (+27) w/w; As % of total V: 42.2%
Fake Vascepa by Manufacturer
Hikma - TRx 17,097; +1,098 w/w; Generic share 36.9%; Total V share 16.0%
Reddy - TRx 20,118; +1,203 w/w; Generic share 43.4%; Total V share 18.8%
Apotex - TRx 8,775; +668 w/w; Generic share 19.0%; Total V share 8.2%
Teva - TRx 314; +60 w/w; Generic share 0.7%; Total V share 0.3%
Vascepa + Fake Vascepa
TRx 106,806; +6.4% (+6,403) w/w; +6.4% y/y
NRx 51,865; +14.2% (+6,451) w/w; +4.5% y/y
Ref 54,942; -0.1% (-48) w/w; +8.2% y/y
Lovaza (Fake & Brand)
TRx 66,087; +8.2% (+5,020) w/w; +4.9% y/y
NRx 32,350; +13.4% (+3,812) w/w; -1.3% y/y
Ref 33,737; +3.7% (+1,209) w/w; +11.6% y/y
Do you have both products? If so, can you run some comparison tests? Break apart and smell, freeze overnight, lab? We can set up a gofundme to fund the lab.
That's correct. I'm out if Denner doesn't win this. I have to draw a line in the sand at some point and it's way way overdue.
Has it ever occurred to these imbeciles that they are incapable of running this company and the best they can do is sell it to the highest bidder?
I truly despise these a**holes.
I totally misread and didn't fully read your post. I thought they were going to call you next week. Clearly my bad.
Agreed?
Do you seriously think there are any sane $AMRN shareholders who say:
— Raf 🍊 (@ra_fun) January 19, 2023
🗣Thank you, I want more of the same?
How about you @Amarincorp, host a Twitter Space where you can say your piece and everyone can ask questions, PUBLICLY? @adenner1 https://t.co/xsEXoTQloc
What a tone deaf PR!
Forget Denner for a second. Just look at your brokerage account and ask if you want the same clowns to keep running Amarin.
All Denner needs to say in his reply is any hint of a buyout and the vote should be nearly unanimous.
Please ask about the testing of Generics, especially this tweet:
I had assumed those would be worthwhile studies to do and be funded, but that did not happen. So, the only data (not anecdote) that exist are the data the FDA would have required and whatever internal data the company would have likely generated themselves (again, me assuming).
— Dr. Deepak L. Bhatt (@DLBHATTMD) November 6, 2022
My email to Denner:
Alex,
As you are trying to schedule a meeting, I want you to be cognizant that there are two Amarin message boards with pretty wide reaches:
IHUB, 400,000 Amarin-related posts.
STOCKTWITS, over 30,000 followers.
Based on recent posts and a Twitter poll that I ran, you have the support of the vast majority of the retail folks but some questions do exist. I am not sure if the following is allowed or even needed, but would you consider running a Twitter Space (like a Zoom, online meeting) to address outstanding questions, concerns, and listen to Amarin-related grievances, etc? A meeting before the meeting.
That is some impressive research. Two things:
1. Simplify for me, please. Can you summarize everything you wrote about Biologix in 1-2 sentences?
2. What is the connection between Biologix & the 12 "clowns" under your theory, just their Arab names?
In the right hands (BP), Vascepa would go through multiple additional trials for additional indications & BP would find a way to differentiate Vascepa from Generics.... reminder that Amarin refused to fund Preston Mason's lab tests, per Dr Bhatt.
Vascepa is infinitely times more valuable in the hands of BP than in the hands of Amarin.
I know this. You know this. Denner knows this. Amarin pretends not to know this.
PS This was supposed to be a reply to North40000
Accurate.
.@Amarincorp $AMRN: .003M? 👏 https://t.co/AIvZ9C1PzW
— Raf 🍊 (@ra_fun) January 17, 2023
Interesting.
.@Amarincorp wants your vote, despite the stock price of $AMRN nosediving by:
— Raf 🍊 (@ra_fun) January 17, 2023
• 95% between FDA approval of Vascepa for CVD reduction (Dec 2019) & Alex Denner's announcement (Jan 2023)
• 82% between Karim Mikhail becoming CEO (Aug 2021) & @adenner1's announcement (Jan 2023) https://t.co/r9w31ZLHKq
Meeting scheduled. Vote for Denner's 7!
https://investor.amarincorp.com/node/22546/html
Good DD. And I hope that people here aren't naive to think that Denner asking for 7 seats isn't a negotiating tactic. Start with 7, end up with 3.
But I'd be happy with whatever he gets, the more the better.
Those who are against Denner getting 7 seats (if him getting 2 seats isn't possible; if it's only either 7 or 0), please guide me through your best case scenario for Amarin for the next 3 years without Denner?
If everything goes according to your dream, under the current management/BOD, what happens operationally & what is the PPS by December 31, 2025?
$AMRN 95% vs 5%
As a shareholder of $AMRN, which team would you choose? #Vascepa
— Raf 🍊 (@ra_fun) January 11, 2023
This is like the most infuriating thing ever for me. Just think about this.. the only way that Amarin loses (very very slightly) is if the tests are conducted and the results show that both products are identical, biologically.
What would Amarin lose? The cost of the study + very few people would switch over.
What are the odds that Generics are identical to Vascepa under the microscope and after a year? Close to 0%, IMO.
On the opposite side of the spectrum, if the results show that the Generics are very different, then it's game over for the Generics.
But if the results are mixed, inconclusive, somewhere in between, we would have a field day with this. We could plant so much doubt (rightfully so), that people and doctors would think twice before switching to Generics. All we would need is a tiny bit of lab data showing they aren't identical.
But without that, we can't do squat and it infuriates the hell out of me.
No one is arguing that the Generics are not infringing, they clearly are.
But if the lab tests were to reveal differences, regardless of how small, if the FDA weren't going to act, the Generics would get obliterated in the court of public opinion. I would gladly lead the way.
I find it nearly impossible to believe that Amarin would not study their competition, especially with the risk/reward being so heavily lopsided in favor of the latter.
But I find it equally impossible to believe that if Amarin did these studies that they would not inform Bhatt, who clearly stated that he thought that Amarin would fund Mason's research but they did not.
Could it be a combination of the two: Amarin ran some quick, simple, cheap preliminary studies, did not see any differences and decided not to spend more money on Mason's complex, long, expensive studies? Idiotic, if true.
Versus what... now, not a single medical professional is saying that the two are different. So could it be any worse than what it currently is?
So perhaps they use every means possible (insurance & Amarin savings card) to give you the cheapest rate. If the rate is still high (above $99), perhaps they guarantee that you pay no more than $99 because they have some sort of an agreement with Amarin?
Amarin did a horrendous job advertisement and explaining this.
Others who do this through BlinkRx, please report your out of pocket cost before/after.
Rose, what are you going to do with FEP? I'm going to try the Formulary Exception route.
Thanks. Does BlinkRx run it through your insurance at all?
Can someone explain how BlinkRx works? I read their website but don't fully understand.
A patient asks their doctor to transfer their Vascepa prescription to BlinkRx instead of their pharmacy. But then what? How does BlinkRx get a cheaper price through the same insurance as it did with the pharmacy?
I'm sorry if I hurt your feelings.
Mind boggling how some intelligent people prefer Amarin to control the BOD rather than Denner.
Any psychologists here? What's this condition called, the battered woman syndrome?
At this point, Denner is almost irrelevant. If Marzan ran against Amarin, he would have my votes because it's impossible to eff it up any worse that how Amarin effed it up.
Yesterday's scripts was their final nail in the coffin for me. And that data was the result of all of their incompetence put together: no fight, no attack, no urgency, no balls, just comatose incompetence.
Does anyone agree? Like & retweet!
Is it hasn't been clear to anyone yet that @Amarincorp aren't capable of selling their only drug VASCEPA & Alex Denner is needed to sell $AMRN to big pharma, 👇 data of weekly scripts makes it 💯 crystal clear!@pfizer @GSK @AstraZeneca @novonordisk @Merck @Novartis @adenner1 https://t.co/xliPh30YBV pic.twitter.com/NBepU9VulZ
— Raf 🍊 (@ra_fun) January 13, 2023
Scripts for week ending January 6, 2023
Drug Industry TRx: +15.7% w/w; +8.9% y/y
Vascepa
TRx 57,127; -2.4% (-1,375) w/w; -19.4% y/y
NRx 25,298; +3.3% (+805) w/w; -19.5% y/y
Ref 31,829; -6.4% (-2,181) w/w; -19.3% y/y
Fake Vascepa
TRx 43,276; +14.2% (+5,366) w/w; As % of total V: 43.1%
NRx 20,116; +25.0% (+4,023) w/w; As % of total V: 44.3%
Ref 23,161; +6.2% (+1,343) w/w; As % of total V: 42.1%
Fake Vascepa by Manufacturer
Hikma - TRx 15,999; +2,327 w/w; Generic share 37.0%; Total V share 15.9%
Reddy - TRx 18,915; +2,307 w/w; Generic share 43.7%; Total V share 18.8%
Apotex - TRx 8,107; +653 w/w; Generic share 18.7%; Total V share 8.1%
Teva - TRx 254; +78 w/w; Generic share 0.6%; Total V share 0.3%
Vascepa + Fake Vascepa
TRx 100,493; +4.1% (+3,991) w/w; +7.0% y/y
NRx 45,414; +11.9% (+4,829) w/w; +2.2% y/y
Ref 54,989; -1.5% (-838) w/w; +11.2% y/y
Lovaza (Fake & Brand)
TRx 61,067; +5 7% (+3,288) w/w; +2.0% y/y
NRx 28,538; +11.6% (+2,962) w/w; -5.2% y/y
Ref 32,529; +1.0% (-915) w/w; +9.3% y/y
1. Pharmacydude should invite himself.
Totally respect her answer. She felt that she could land herself in hot water because it’s all drug recommendations and evaluations. We at @SessionsTlc strive not be part of the echo chamber and always try and report on all the science good and bad.
— The Long Covid Sessions Podcast (@SessionsTlc) January 13, 2023
Curious, how many vaxx boosters did you get?
I'm not saying whoaaaa yet, because it could be an imposter but this account was created in 2013 and he liked Amarin-related posts and just followed me. Possibly a big whoaaaa.
https://stocktwits.com/rafunrafun/message/506148420